Enzo Biochem — Proxy Contest (December 2015)
96 slides from Enzo Biochem's proxy contest presentation, Dec 10, 2015
Slide 1: December Investor Presentation
December 2015 www.enzo.com December Investor Presentation
Slide 2: Disclaimer
1 DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward - looking" statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such statements include
Slide 3: Proxy solicitation notice
2 Enzo Biochem, Inc . (the “Company”) has filed a definitive proxy statement with the U . S . Securities and Exchange Commission (the "SEC") with respect to its 2015 Annual Meeting of Shareholders and intends to file a definitive proxy statement as well . The definitive proxy statement and white pro
Slide 4: Table of Contents
3 TABLE OF CONTENTS Page Executive Summary 4 Company Overview 10 Molecular Diagnostics Industry 22 Enzo’s Unique Solution 30 Lone Star’s Lack of Value - Add 40 Addressing Lone Star’s Uninformed Critique of Enzo 75 Enzo’s Leadership and Stewardship 81 Appendix 89
Slide 5: Executive Summary
December 2015 www.enzo.com Executive Summary 4
Slide 6: Enzo's Time Is Now
5 ENZO’S TIME IS NOW ENZO IS POSITIONED TO CREATE SUSTAINED VALUE FOR ITS SHAREHOLDER S Industry Challenge Enzo Solution While demand for MDx is rapidly increasing , reimbursement is rapidly declining – and lab margins could decline by an additional 20 - 30 percentage points under new payment poli
Slide 7: Lone Star Value's Lack of Specificity and Value-Add
6 LONE STAR VALUE’S LACK OF SPECIFICITY AND VALUE - ADD An investment manager called Lone Star Value Management LLC (“Lone Star”) with a 1.23% position in Enzo is currently seeking 40% representation on Enzo’s board (1) We believe Lone Star’s interests are not aligned with other shareholders – L
Slide 8: Enzo's strengths versus Lone Star's approach
7 x Solid corporate strategy and well positioned to execute in the current environment x Delivering solid returns to shareholders - 3 - year TSR of 71.9% x Innovative Technology and P atent Estate beginning to create value x Management team with depth and experience…expanding in core areas x Indepen
Slide 9: The Choice for Shareholders Is Clear
x A business model and operational structure that are positioned to address the imminent needs of the growing but challenged MDx industry x The ability to further leverage Enzo’s vertically integrated business structure to create value for shareholders x A board and management team with a deep under
Slide 10: Enzo Is Positioned to Thrive NOW
9 Enzo Is Positioned to Thrive NOW
Slide 11: Company Overview
December 2015 www.enzo.com Company Overview 10
Slide 12: Enzo Is an Integrated Diagnostics Entity
11 ENZO BIOCHEM ENZO IS AN INTEGRATED DIAGNOSTICS ENTITY THAT IS UNIQUELY STRUCTURED TO CAPITALIZE ON ONGOING REIMBURSEMENT PRESSURES IN THE MOLECULAR DIAGNOSTICS MARKET Enzo’s vertically integrated structure positions it to benefit as a disruptor in molecular diagnostics : Biotech : Develops te
Slide 13: Enzo's Structure
12 ENZO’S STRUCTURE Commercial Optimization VERY DIFFICULT TO REPRODUCE WHICH HAS CREATED COMPETITIVE ADVANT AGE BIOTECH ▪ Market - Focused Innovation ▪ Technology Development ▪ Platform Development ▪ Intellectual Property MD x PRODUCTS ▪ Product Development ▪ Manufacturing ▪ Regulatory Validation ▪
Slide 14: Why Enzo Can Deliver 30%-50% Savings to Market
13 WHY ENZO BELIEVES IT CAN DELIVER 30% - 50% SAVINGS TO MARKET Average Gross Margin of Clinical Services Companies (1) ~30% Potential MDx Savings: Cumulative Royalty Relief Enzo owns all of its IP Intellectual property generation already paid for Lower Cost of Goods Enzo’s cumulative technolo
Slide 15: The Synergies of Enzo's Structure
Biotech MDx Products Clinical Services 14 THE SYNERGIES OF ENZO’S STRUCTURE Note: Block sizes are purely illustrative (1) Company estimates THE SYNERGISTIC VALUE OF THE WHOLE EXCEEDS THE SUM OF THE PARTS AND ALLOWS ENZO TO CONTINUE TO EXECUTE ON ITS STRATEGY TO DRIVE SHAREHOLDER VALUE Biotech Ex
Slide 16: The Market Is Starting to Recognize Enzo's Potential
15 THE MARKET IS STARTING TO RECOGNIZE ENZO’S COMPELLING POTENTIAL 6 - Month Total Shareholder Return Note: Selected Lab Peers: GHDX, NEO, SQNM, SHL, NTRA, and VCYT (Median value used) Note: Selected Life Science Peers: AFFX, NSTG, EXQ, HBIO, and TECH (Median value used) Source: Capital IQ as of Dec
Slide 17: Recent Catalysts
0 100 200 300 400 500 600 700 800 900 1000 $2.50 $3.00 $3.50 $4.00 $4.50 $5.00 Volume (Thousands) Stock Price October 29, 2015: Enzo announces it has demonstrated new thresholds of sensitivity and breadth for its assay for the measurement of Hepatitis C virus (HCV) viral load November 17, 2015: Enzo
Slide 18: Enzo Is on a Path to Create Sustained Shareholder Value
17 ENZO IS ON A PATH TO CREATE SUSTAINED SHAREHOLDER VALUE $15,822 $17,090 $15,000 $15,500 $16,000 $16,500 $17,000 $17,500 Q1 2015 Q1 2016 Clinical Laboratory Services Revenue 36.0% 39.5% 34.0% 35.0% 36.0% 37.0% 38.0% 39.0% 40.0% Q1 2015 Q1 2016 Clinical Laboratory Services Gross Margin “FQ1 (Oct) r
Slide 19: Enzo's Performance Versus Peers
18 ENZO’S PERFORMANCE VERSUS PEERS 1.6% 0.9% 0.3% - 4.0% -10.0% -8.0% -6.0% -4.0% -2.0% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% Life Science Peers All Peers Lab Peers Enzo Biochem Inc. 90.7% 5.2% 3.8% - 6.9% -20.0% 0.0% 20.0% 40.0% 60.0% 80.0% 100.0% Enzo Biochem Inc. Life Science Peers All Peers Lab Peers 7
Slide 20: Improving Operating Efficiencies
6.1% 4.2% 3.3% 3.4% 0% 1% 2% 3% 4% 5% 6% 7% FY 2012 FY 2013 FY 2014 FY 2015 46.5% 46.6% 43.6% 42.1% 39% 40% 41% 42% 43% 44% 45% 46% 47% FY 2012 FY 2013 FY 2014 FY 2015 19 ENZO IS WORKING DILIGENTLY TO IMPROVE OPERATING EFFICIENCIES PROVEN COMMITMENT TO IMPROVE EFFICIENCIES FOR THE BENEFIT OF SHAREHO
Slide 21: Enzo's Extremely Efficient R&D Investment
R&D Spend 5 yr 10 yr Sales TEV $273 $406 281 $762 181 315 137 261 63 63 189 392 43 43 48 157 17 (1) 41 (1) 98 189 20 ENZO’S EXTREMELY EFFICIENT R&D INVESTMENT ($ in millions) Note: Enzo figures calendarized from fiscal year ending 7/31 Source: Company filings (1) Excludes Therapeutics R&D Cumulative
Slide 22: Effective Return on IP Litigation Investment
Enzo has consistently been at the frontier of innovation, committed to investing in the development of disruptive technologies Having a wide range of applications, Enzo’s IP estate of patents (of which our CEO is co - inventor) has been regularly infringed upon, enriching a number of major compa
Slide 23: Molecular Diagnostics Industry
December 2015 www.enzo.com Molecular Diagnostics Industry: Challenging Environment Creates Significant Opportunities for Enzo 22
Slide 24: MDx Market Growth
23 MD x MARKET GROWTH $4.6 $4.9 $5.2 $5.6 $6.0 $6.5 $7.1 $3 $4 $4 $5 $5 $6 $6 $7 $7 $8 2012 2013 2014 2015 2016 2017 2018 ($ in billions) In the span of 25 years, molecular diagnostics have burgeoned from a practically non - existent market of approximately $10 million in product sales to $ 5.2 bi
Slide 25: MDx Market Challenges
24 MD x MARKET CHALLENGES Demand for MDx is rapidly increasing, and we believe it is growing at 2x the rate of the overall diagnostic market (1) Despite growing demand, reimbursement for MDx tests is in long - term decline (1) MDx margins within labs could decline by another 20 - 30 percentage
Slide 26: Impact of Impending Reimbursement Cuts
(60.0%) (50.0%) (40.0%) (30.0%) (20.0%) (10.0%) 0.0% 10.0% 20.0% 30.0% 40.0% Genomic Health Inc. Veracyte, Inc. CareDx, Inc. 25 IMPACT OF IMPENDING REIMBURSEMENT CUTS ON DIAGNOSTIC COMPANIES “We expect several diagnostics stocks to trade off sharply following announced price cuts by the Centers for
Slide 27: Clinical Labs Under Pressure
26 CLINICAL LABS UNDER PRESSURE “There are three key pieces of information that were released by CMS on Friday, September 25, including: 1) a proposed rule to change Medicare Clinical Lab Fee Schedule reimbursement based on the PAMA legislation enacted in 2014, 2) proposed methodologies for pricing
Slide 28: Operational efficiencies maxed out
27 OPERATIONAL EFFICIENCIES HAVE ALREADY VIRTUALLY MAXED OUT Clinical labs have made substantial efforts to reduce costs and, we believe, have focused their effort on labor expenses Market consolidation is largely complete Due to government - mandated staffing levels, clinical labs are no lo
Slide 29: The Rigid Relationships Between Labs and MDx Providers
28 THE RIGID RELATIONSHIPS BETWEEN LABS AND MDX PROVIDERS Closed MDx System MDx Test “Company A” makes the MDx test “Company A” also makes the MDx s ystem that can only use “Company A’s ” MDx t est Closed - end systems are developed by MDx companies to perform MDx tests that only accept propri
Slide 30: MDx Market Has Material Inefficiencies
29 MD x MARKET HAS MATERIAL INEFFICIENCIES Intellectual Property Biotech Innovation, Technology, and Test Platforms MDx Develop, Validate, and Manufacture Products Product Distribution, Sales, and Marketing Clinical Services $ $ $ $ Billing Payors Cost Cost Cost Cost Reimbursement Pressures The Mult
Slide 31: Enzo's Unique Solution
December 2015 www.enzo.com Enzo’s Unique Solution: A vertically integrated Company with disruptive technology to sustainably solve the MDx market’s problems 30
Slide 32: Enzo Is Structured to Meet the Market Challenges
31 ENZO IS STRUCTURED TO MEET THE MARKET CHALLENGES WITH OUR VERTICALLY INTEGRATED STRUCTURE, WE AVOID THE INTERMEDIATE COSTS AT EACH STEP... SAVINGS THAT WE PASS ON TO THE MARKET AND VALUE WE CAN DELIVER TO OUR SHAREHOLDERS Biotech Leverages Enzo’s extensive IP to develop technologies and platfor
Slide 33: Vertical Integration Eliminates Cost Redundancies
32 ENZO’S VERTICAL INTEGRATION ELIMINATES COST REDUNDANCIES Intellectual Property Biotech Innovation, Technology, and Test Platforms MDx Develop, Validate, and Manufacture Products Product Distribution, Sales, and Marketing Clinical Services $ $ $ $ Billing Payors Cost Cost Cost Cost Reimbursement P
Slide 34: Why Enzo Can Deliver 30%-50% Savings to Market
33 WHY ENZO BELIEVES IT CAN DELIVER 30% - 50% SAVINGS TO MARKET Average Gross Margin of Clinical Services Companies (1) ~30% Potential MDx Savings: Cumulative Royalty Relief Enzo owns all of its IP Intellectual property generation already paid for Lower Cost of Goods Enzo’s cumulative technolo
Slide 35: The Open System Opportunity
34 THE “OPEN SYSTEM” OPPORTUNITY Enzo makes multiple high - quality MDx Assays Which are lower - priced and can fit into most “open ” MDx systems Recently, inexpensive open systems have become widely available, but high - value content is lacking due to IP barriers – this presents a material o
Slide 36: Enzo's Solution: Vertical Integration
Innovation & IP Technology Platform Manufacturing Technology Validation Products Services Biotech Competitors P P O O O O MDx Competitors Via Licenses P P P O Clinical Service Competitors O O O O O P P P P P P P 35 ENZO’S SOLUTION: VERTICAL INTEGRATION BIOTECH, MD x, AND CLINICAL SERVICES COMPANIES
Slide 37: Enzo Has a Robust MDx Pipeline
36 ENZO HAS A ROBUST MD x PIPELINE Product / Test Description Expected Availability (1) Platform Annual Market Opportunity (2) HPV E6/E7 Detection Available FLOWSCRIPT™ GENE EXPRESSION $200mm+ product $500mm service HCV Viral Load Available AMPIPROBE™ REAL - TIME AMPLIFICATION AND DETECTION $300mm p
Slide 38: Clinical Services
37 CLINICAL SERVICES x Technical Expertise x Accreditation x Logistics x IT – Lab x IT – Clients – Integrated into customers’ operations x Financial Services x Payor Relations – In - network with most major payors x Reputation for Excellence x Marketing and Sales ENZO HAS BUILT A HIGHLY SCALABLE CLI
Slide 39: Enzo's Market
38 ENZO’S MARKET Physicians Clinical Labs Pharma CROs Payors
Slide 40: Summary
39 SUMMARY The Company continually evaluates its own technologies and platforms and selects those to further advance based on the following criteria: Products that solve problems for clinical labs and have existing market opportunities Products that can be sold at 30% - 50% less than our compe
Slide 41: Lone Star's Lack of Value-Add
December 2015 www.enzo.com Lone Star’s Lack of Value - Add 40
Slide 42: Lone Star Value's Lack of Specificity and Value-Add
41 LONE STAR VALUE’S LACK OF SPECIFICITY AND VALUE - ADD An investment manager called Lone Star Value Management LLC (“Lone Star”) with a 1.23% position in Enzo is currently seeking 40% representation on Enzo’s board (1) We believe Lone Star’s interests are not aligned with other shareholders –
Slide 43: Is Lone Star a Shareholder or a Trader?
42 IS LONE STAR A SHAREHOLDER OR A TRADER? Common Stock 5,000 10/1/15 Common Stock 10,000 10/19/15 Common Stock (55,000) 10/30/15 Common Stock (5,000) 10/30/15 Common Stock (25,000) 11/2/15 Common Stock (5,000) 11/2/15 Common Stock (31,300) 11/4/15 Common Stock (2,236) 11/4/15 Common Stock (18,897)
Slide 44: Lone Star's Nominees Are Not Independent
43 LONE STAR’S NOMINEES ARE NOT INDEPENDENT When Mr. Eberwein first suggested Mr. Angelis and Mr. Climaco for the Board of Enzo, he asserted that they were “completely independent” and that he had met them on the Board of Digirad (1) A closer examination, however, shows in no uncertain terms tha
Slide 45: Independent Directors?
44 INDEPENDENT DIRECTORS? Jeff Eberwein Dimitrios Angelis John Climaco Chuck Gillman Dilip Singh Supporter Largest Shareholder Largest Shareholder Richard Coleman Jr. Boston Avenue Capital, LLC Proponent Source: FactSet BANKRUPT (Climaco is EVP of parent company)
Slide 46: Director Relationships Since 2012
45 DIRECTOR RELATIONSHIPS SINCE 2012 WE BELIEVE THAT LONE STAR OBTAINING A DIRECTOR ON ENZO’S BOARD A S A BENEFIT IN AND OF ITSELF TO LONE STAR, BUT NOT NECESSARILY TO THE BENEFI T TO ALL OF ENZO’S SHAREHOLDERS Total Public Boards Boards with Eberwein Boards with Climaco Boards with Angelis Jeffrey
Slide 47: Lack of Independence: Digirad's Failed Bid for PDI
46 LACK OF INDEPENDENCE: DIGIRAD’S FAILED BID FOR PDI In October 2013, John Climaco joined the Board of PDI, Inc. On October 29, 2014, John Climaco resigned from PDI’s Board of Directors On October 29, 2014, the same day as Climaco’s resignation , Digirad, where Mr. Eberwein is a director, sen
Slide 48: What's Going On at Digirad?
47 WHAT’S GOING ON AT DIGIRAD ? On July 24, 2015, the Company’s majority - owned Polish subsidiary, Perma - Fix Medical and Digirad Corporation, a Delaware corporation (“ Digirad ”), Nasdaq: DRAD, entered into a multi - year Tc - 99m Supplier Agreement (the “Supplier Agreement”) and a Series F Stock
Slide 49: Digirad and Permafix
48 DIGIRAD AND PERMAFIX NOW PERMAFIX HAS A SLIDE ON DIGIRAD IN ITS INVESTOR PRESENTATION, WHY?
Slide 50: Lone Star Nominee: John Climaco
49 LONE STAR NOMINEE: JOHN CLIMACO Enzo’s management team has known Mr. Climaco for approximately three years We were first introduced to Mr. Climaco when he approached Enzo in an effort to explore channels of distribution for his Axial Biotech product, which we turned down after being entirely
Slide 51: Nominee failed to disclose significant facts
50 We are concerned that a Lone Star nominee failed to disclose significant facts in his background and only disclosed them upon questioning by our Nominating and Governance Committee
Slide 52: John Climaco Case Study: Essex Rental Corp.
- 64.1% -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% 60.0% 80.0% 100.0% 51 JOHN CLIMACO CASE STUDY: ESSEX RENTAL CORP. February 26, 2015: Casey Capital LLC filed Schedule 13D June 5, 2015: Essex announced the Board’s decision to accept the nomination of John Keddie and John Climaco to the board Sour
Slide 53: John Climaco Case Study: ALCO Stores
52 JOHN CLIMACO CASE STUDY: ALCO STORES (100%) -120.0% -100.0% -80.0% -60.0% -40.0% -20.0% 0.0% February 18, 2014: Concerned ALCO Stockholders (“CAS”) announced its intent to nominate board candidates in ALCO’s 2014 election August 29, 2014: ALCO announced the completion of its annual meeting where
Slide 54: Lone Star Nominee: Dimitrios Angelis
53 LONE STAR NOMINEE: DIMITRIOS ANGELIS Mr. Angelis is currently on the boards of Digirad (with Mr. Eberwein and Mr. Climaco) and Ameri100 Mr. Angelis’ most recent full - time position was serving as CEO of On Track Innovations (where Mr. Eberwein, Mr. Gillman, and Mr. Singh were all on the Boar
Slide 55: Lone Star Nominees Have No Plan
54 LONE STAR NOMINEES HAVE NO PLAN Enzo acknowledges that the Company has yet to achieve its full potential We have been executing on a multi - year strategic plan to dramatically improve performance and create sustained value for shareholders Our strategy is beginning to bear the fruit of thi
Slide 56: Mr. Eberwein's track record as activist investor
55 We believe that Mr. Eberwein’s track record as an activist investor and corporate director appears to be quite poor S ince starting his activist fund in 2012, Mr. Eberwein has been one of the most activist investors in the U.S., routinely targeting smaller - cap companies in diverse industrie
Slide 57: TSR Since Lone Star/Climaco Campaigns
56 TSR SINCE LONE STAR/CLIMACO CAMPAIGNS 125.9% 74.5% 56.2% - 8.1% - 11.5% - 20.0% - 21.8% - 26.9% - 34.2% - 35.3% - 38.9% - 47.06% - 54.1% - 56.8% - 64.1% - 83.1% - 87.0% - 91.1% - 99.8% - 99.9% -100.0% -50.0% 0.0% 50.0% 100.0% 150.0% LONE STAR’S TRACK RECORD WE BELIEVE SPEAKS FOR ITSELF Median = N
Slide 58: Lone Star Value Management Campaign Overview
Lone Star’s Investments that Have Seen Increased Shareholder Value 57 LONE STAR VALUE MANAGEMENT CAMPAIGN OVERVIEW Campaigns in Which Lone Star Has Diminished Shareholder Value 15 3 LONE STAR SHOULD BE THRILLED WITH ITS RETURN ON ENZO Source: FactSet
Slide 59: Jeffrey Eberwein Case Study: Aetrium
58 JEFFREY EBERWEIN CASE STUDY: AETRIUM -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% 60.0% 80.0% August 14, 2012: Jeffrey Eberwein and Archer Advisors LLC filed a joint Schedule 13D (Concerned Aetrium Shareholders (“CAS”)) reporting a 16.7 % stake in the Company November 29, 2012: CAS filed a lawsui
Slide 60: Lone Star Case Study: Antares
59 LONE STAR CASE STUDY: ANTARES “The Board of Directors believe Lone Star Value Management brought nothing of merit to Antares and the lack of veracity of their statements was clearly demonstrated by the failure of Jeffrey Eberwein to attend the General Meeting he imposed upon Shareholders at which
Slide 61: Lone Star Case Study: Aviat
60 LONE STAR CASE STUDY: AVIAT -50.00% -40.00% -30.00% -20.00% -10.00% 0.00% 10.00% 20.00% October 6, 2014: Lone Star issues a press release and disclosed its intent to nominate six candidates for election to Aviat’s board at the 2014 annual meeting January 12, 2015: Aviat announced the reaching of
Slide 62: Lone Star Case Study: CIBER
61 LONE STAR CASE STUDY: CIBER -45.0% -40.0% -35.0% -30.0% -25.0% -20.0% -15.0% -10.0% -5.0% 0.0% 5.0% 10.0% February 27, 2014: Lone Star submitted formal notice to nominate three candidates to CIBER’s Board at the 2015 annual meeting April 20, 2014: CIBER announced the nomination of a new independe
Slide 63: Lone Star Case Study: Dakota Plains Holdings
-90.00% -80.00% -70.00% -60.00% -50.00% -40.00% -30.00% -20.00% -10.00% 0.00% 10.00% 62 LONE STAR CASE STUDY: DAKOTA PLAINS HOLDINGS December 15, 2014: Lone Star, a 7.3% holder, urged the company’s B oard to use a Master Limited Partnership for the Pioneer transloading business and to initiate a rev
Slide 64: Lone Star Case Study: Endeavour International
-80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% 60.0% 63 LONE STAR CASE STUDY: ENDEAVOUR INTERNATIONAL July 23, 2013: Endeavour Investors for Shareholder Value (EISV) (Including Jeff Eberwein) filed a joint 13D reporting a combined 16.7% stake. EISV urged the company to evaluate strategic alternatives.
Slide 65: InfuSystem Case Study
64 INFUSYSTEM CASE STUDY A COMPANY FOUNDED BY CHUCK GILLMAN AND SUPPORTED BY JEFFREY EBER WEIN ENTERED A SETTLEMENT WITH INFUSYSTEM TO PLACE CHUCK GILLMAN, JOHN CLIMACO, AND DILIP SINGH ON THE BOARD On January 18, 2012, Meson Capital Partners, Kleinheinz Capital Partners, and Boston Avenue Capital
Slide 66: InfuSystem Case Study (cont.)
- 11.52% -30.00% -25.00% -20.00% -15.00% -10.00% -5.00% 0.00% 5.00% 10.00% 15.00% 20.00% 65 INFUSYSTEM CASE STUDY (CONT.) 68.64% -40.00% -20.00% 0.00% 20.00% 40.00% 60.00% 80.00% 100.00% 120.00% 140.00% 160.00% 180.00% Stock Performance with Climaco on Board Stock Performance after Climaco Left the
Slide 67: Lone Star Case Study: Hudson Global
66 LONE STAR CASE STUDY: HUDSON GLOBAL -50.0% -40.0% -30.0% -20.0% -10.0% 0.0% 10.0% 20.0% January 21, 2014: Lone Star Value Management, Bradley Radoff, and Richard Coleman filed a joint Schedule 13D, reporting a combined stake of 6.8% December 2, 2013: Heartland Advisors, Charles Gillman, and other
Slide 68: Eberwein Case Study: MAG Silver
67 EBERWEIN CASE STUDY: MAG SILVER -60.0% -50.0% -40.0% -30.0% -20.0% -10.0% 0.0% 10.0% 20.0% 30.0% 40.0% April 3, 2012: Mason Hill Advisors filed a Schedule 13D, reporting an 8.5% stake in the Company and that it had engaged in strategic alternatives discussions with the company June 29, 2012: Jeff
Slide 69: Lone Star Case Study: Miller Energy
-120.0% -100.0% -80.0% -60.0% -40.0% -20.0% 0.0% 68 LONE STAR CASE STUDY: MILLER ENERGY December 17, 2013: Concerned Miller Shareholders (CMS), led by Bristol Capital Advisors and Lone Star, 4.7% holders, disclosed the nomination of 10 board members at Miller’s 2014 annual meeting March 31, 2014: Th
Slide 70: Lone Star Case Study: Novation
69 LONE STAR CASE STUDY: NOVATION -60.00% -40.00% -20.00% 0.00% 20.00% 40.00% 60.00% 80.00% April 22. 2015: Novation Companies announced in a press release a settlement agreement with Lone Star. Per the agreement, the company would appoint Jeffrey Eberwein and Robert G. Pearse to the Board. The comp
Slide 71: Lone Star Case Study: O2Micro
70 LONE STAR CASE STUDY: O2MICRO -30.0% -20.0% -10.0% 0.0% 10.0% 20.0% 30.0% 40.0% November 25, 2014: Lone Star filed a Schedule 13D, reporting a stake of 5.6% in O2Micro. It proposed that the company streamline operations, repurchase shares/issue a dividend, liquidate long - term equity investments
Slide 72: Lone Star Case Study: Penn Virginia Corporation
71 LONE STAR CASE STUDY: PENN VIRGINIA CORPORATION -100.0% -90.0% -80.0% -70.0% -60.0% -50.0% -40.0% -30.0% -20.0% -10.0% 0.0% June 26, 2015: Lone Star, a 2.8% holder owning 1.975 million shares of Penn Virginia stock, issued a press release suggesting the company assesses strategic alternatives Sep
Slide 73: Lone Star Case Study: Rentech
72 LONE STAR CASE STUDY: RENTECH -100.0% -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% January 13, 2014: The Concerned Rentech Shareholders Group (Engaged Capital and Lone Star Value Management) (CRS) announced the nomination of four directors to the Board of Rentech March 20, 2014: CRS filed a preli
Slide 74: Lone Star Case Study: SWS Group
73 LONE STAR CASE STUDY: SWS GROUP -15.00% -10.00% -5.00% 0.00% 5.00% 10.00% January 13, 2014: Lone Star, a 2.3% holder, issued a press release urging the company to put itself up for sale after the Hilltop Holdings offer of $7 per share August 8, 2014: Lone Star reported a 5.5% stake in the company
Slide 75: Enzo is open to directors nominated by shareholders
74 Enzo is open to directors nominated by shareholders – as was the case when Dov Perlysky was placed on Enzo’s Board – but the Nominating and Governance Committee thoroughly vetted Lone Star’s nominees and unanimously determined that adding Lone Star’s nominees to Enzo’s Board in no way provides un
Slide 76: Addressing Lone Star's Uninformed Critique of Enzo
December 2015 www.enzo.com Addressing Lone Star’s Uninformed Critique of Enzo 75
Slide 77: "Poor Financial Performance"
76 “POOR FINANCIAL PERFORMANCE” In the Company’s preliminary proxy statement, Lone Star criticizes the Company as having poor financial performance Lone Star chooses to “stop the clock” on Enzo’s share performance before the Company’s stock appreciated an additional 50% Does Lone Star deciding t
Slide 78: Concerns Whether Director Dov Perlysky Truly Represents Shareholders
77 “CONCERNS WHETHER DIRECTOR DOV PERLYSKY TRULY REPRESENTS THE COMPANY’S PUBLIC SHAREHOLDERS” “We also have concerns whether D irector Dov Perlysky truly represents the Company’s public shareholders, as he is the son - in - law of Rosalind Davidowitz, who had an approximate 9.3% ownership interest
Slide 79: Classified Board Structure, Corporate Governance
78 “CLASSIFIED BOARD STRUCTURE, POOR CORPORATE GOVERNANCE, AND LIMITATIONS ON SHAREHOLDER RIGHTS” In yet another demonstration of what we believe is its lack of understanding of our business, Lone Star pays special attention to criticizing Enzo’s classified board Enzo’s classified board is a nec
Slide 80: "Related-Party Transactions"
79 “RELATED - PARTY TRANSACTIONS” In its preliminary proxy statement, Lone Star expresses concerns regarding the Company’s “ related - party transactions” Although Lone Star repeatedly states "transactions ” to suggest that there are multiple, there is, in fact, a single related - party transact
Slide 81: Clinical lab lease
80 Lone star’s attempt to depict the Company’s clinical lab lease as somehow unfair or enriching the management team at the expense of shareholders, we believe, demonstrates either: a complete misunderstanding of the facts, or a further attempt to potentially mislead shareholders
Slide 82: Enzo's Leadership and Stewardship
December 2015 www.enzo.com Enzo’s Leadership and Stewardship 81
Slide 83: Elazar Rabbani and Barry Weiner
82 ELAZAR RABBANI, Ph . D . , is an Enzo Biochem founder and has served as the Company’s Chairman of the Board and Chief Executive Officer since its inception in 1976 and Secretary since November 25 , 2009 . Dr . Rabbani has authored numerous scientific publications in the field of molecular biology
Slide 84: Dieter Schapfel, M.D.
83 DIETER SCHAPFEL, M . D . , Chief Medical Director for Enzo Clinical Labs, has been employed with the Company since 2012 , initially as a consulting pathologist . Dr . Schapfel served as Medical Director of Pathology at Southside Hospital – North Shore/Long Island Jewish Health System from 2006 to
Slide 85: Independent Director Bortz
84 Mr . Bortz is an Independent Director of Enzo Biochem, Inc. He co - founded CREO and leads its investment management business. With over 19 years of experience in developing and managing investments for high - net - worth individuals, families, and institutions, Mr. Bortz has generated sizeable r
Slide 86: Dov Perlysky
85 DOV PERLYSKY Mr . Perlysky is an Independent Director of Enzo Biochem , Inc .. He is also an Independent Director at Highlands Bancorp, Inc . , Independent Director at Pharma - Bio Serv , Inc . , and Managing Member at Nesher LLC . He is on the Board of Directors at Enzo Biochem , Inc .; Oak Tree
Slide 87: Bernard L. Kasten, M.D.
86 BERNARD L. KASTEN, M.D Mr . Kasten is an Independent Director at Enzo Biochem , Inc .. Dr . Kasten has served as a director and Executive Chairman of GeneLink Inc . since 2007 and CEO since December 2010 (GNLK : OTCBB) . He served as Chairman of the Board of Cleveland Biolabs , Inc . (CBLI : NASD
Slide 88: The Choice for Shareholders Is Clear
x A business model and operational structure that are positioned to address the imminent needs of the growing but challenged MDx industry x The ability to further leverage Enzo’s vertically integrated business structure to create value for shareholders x A board and management team with a deep under
Slide 89: Enzo Is Positioned to Thrive NOW
88 The Choice for Shareholders Is Clear: Enzo Is Positioned to Thrive NOW
Slide 90: Appendix
December 2015 www.enzo.com Appendix 89
Slide 91: Two of Enzo's Proprietary Platforms
90 JUST TWO OF ENZO’S PROPRIETARY PLATFORMS AMPIPROBE ™ FLOWSCRIPT ™ Less Sample x Allows paneling/reduced reaction volume/lower prep costs Multiplex Capability x Able to run up to 30 assays simultaneously Zero Background x After more than 60 cycles x Competitors have issues 100% Concordance x Exist
Slide 92: AmpiProbe HCV platform
91 AMPIPROBE can be run on virtually all commonly available open systems This test platform is formatted for both multiplexing (1) and paneling (2) This increases the number of tests that can be run on a single specimen It reduces the cost per test – and reduces the need for patients to prov
Slide 93: AmpiProbe HCV: Huge Opportunity
92 (1) Company estimates AMPIPROBE™ HCV: HUGE OPPORTUNITY World Health Organization Approximately 500,000 people die each year from hepatitis C - related liver diseases 130 - 150 million people globally have chronic hepatitis C infection Early diagnosis can prevent health problems that may result fr
Slide 94: FlowScript HPV
93 FLOWSCRIPT is formatted for use with commonly available lab instrumentatio n It is clinically validated across numerous instrument manufacturers, for virtually all high - risk HPV subtypes, on more than 1,500 specimens, and using both leading sample collection devices to assure the widest pos
Slide 95: FlowScript HPV E6/E7: Growth Potential
94 (1) Centers for Disease Control and Prevention (2) Global Industry Analysts, Inc. FLOWSCRIPT™ HPV E6/E7: GROWTH POTENTIAL Cervical cancer is the most common HPV - associated cancer among women In general, HPV is thought to be responsible for more than 90% of anal and cervical cancers (1) Most peo
Slide 96: Contact Information
95 CONTACT INFORMATION Bruce H. Goldfarb/Patrick J. McHugh/Michael Fein (212) 297 - 0720 / (877 ) 629 - 6356 [email protected] Shareholders